“…While studies have described anti-diabetic activity in withanolides including coagulanolide (Beg et al, 2014;Singh et al, 2012;Maurya et al, 2008), and 4b-hydroxywithanolide E (Takimoto et al, 2014), this is the first study documenting the anti-diabetic activity of withaferin A. Previously implicated as a possible treatment for cancer (Grover et al, 2010), inflammation (Maitra et al, 2009), and for inhibiting angiogenesis (Mohan et al, 2004), withaferin's hypoglycemic activity had not previously been documented.…”